High-Throughput Drug Discovery of the First Inhibitors of a Novel Oncogene in Cancer

Tuesday, February 8, 2022

2:30 PM – 2:50 PM

Location: Exhibition Theater (#2644 in Exhibition)

Sponsored By

Daniel LaBarbera, PhD

Professor of Pharmaceutical Sciences and Director of The Center for Drug Discovery, Co-Director, Drug Discovery and Development Shared Resource (D3SR)
Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus., Colorado, United States

Chromodomain Helicase DNA Binding Protein 1 Like (CHD1L), also known as Amplified in Liver Cancer 1 (ALC1), is a chromatin remodeling enzyme and new oncogene implicated in tumor progression, multidrug resistance, and metastasis in many types of cancer. This presentation will discuss the high-throughput (HTS and HCS) drug discovery and lead validation of the first-in-class inhibitors of CHD1L.